Last checked at 
(Sharecast News) - Alliance Pharma said in an update on Wednesday that its business was in "good health", with demand for its brand strong.
The AIM-traded firm, which was holding its annual general meeting, said the integration of ScarAway and the rights to Kelo-cote in the United States, acquired in March, was progressing "well".
Its board chair David Cook told shareholders that, in line with what it said at its full-year results in March, the company expected 2022 financial year performance to be weighted to the second half.
"[This is] due to our anticipated sales trajectory for Amberen and Nizoral, together with temporary disruption to our supply chain through Covid-related lockdowns in China, which is now beginning to ease," Cook said.
"We remain confident in our ability to deliver full year financial performance in line with market expectations."
Alliance said it would make further commentary on its first half performance in a trading update in July.
At 1429 BST, shares in Alliance Pharma were down 4.39% at 108.8p.
Reporting by Josh White at Sharecast.com.
